Cartesian Therapeutics reports Q2 net income $15.9M; initiates Phase 3 AURORA trial for Descartes-08 in MG

Cartesian Therapeutics, Inc.

2025-Q2 EPS reported -$0.07 revenue$1,398,000

Cash, equivalents and restricted cash $162.1M as of June 30, 2025; expected to fund operations into mid-2027.
Net income $15.9M ($0.51 basic EPS) vs $13.8M ($0.58 basic EPS) in Q2 2024.
R&D expenses $14.9M, up from $12.7M, driven by Phase 3 AURORA trial costs.
Preliminary Phase 2 data for Descartes-08 in SLE expected in 2H25; pediatric basket trial initiation also expected in 2H25.
Phase 3 AURORA trial of Descartes-08 in myasthenia gravis dosed first participant in May 2025; primary endpoint at Month 4.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.